Brokers Set Expectations for RCKT FY2026 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Analysts at Lifesci Capital issued their FY2026 earnings estimates for shares of Rocket Pharmaceuticals in a report released on Thursday, February 26th. Lifesci Capital analyst P. Dolezal forecasts that the biotechnology company will post earnings per share of ($1.81) for the year. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($2.83) per share.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.04. During the same period last year, the company earned ($0.62) EPS.

Several other equities analysts have also weighed in on RCKT. Bank of America reduced their price objective on Rocket Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Wedbush reaffirmed an “outperform” rating and set a $16.00 price target on shares of Rocket Pharmaceuticals in a research report on Friday, November 7th. Morgan Stanley set a $5.00 price objective on shares of Rocket Pharmaceuticals in a research note on Thursday, January 8th. JPMorgan Chase & Co. downgraded shares of Rocket Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research note on Tuesday, November 18th. Finally, TD Cowen raised shares of Rocket Pharmaceuticals to a “hold” rating in a research report on Friday, December 19th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $14.50.

Rocket Pharmaceuticals Price Performance

RCKT stock opened at $5.01 on Monday. The company has a market cap of $543.94 million, a PE ratio of -2.49 and a beta of 0.39. The company has a current ratio of 6.38, a quick ratio of 6.38 and a debt-to-equity ratio of 0.07. The stock has a 50-day moving average price of $3.62 and a two-hundred day moving average price of $3.45. Rocket Pharmaceuticals has a 12-month low of $2.19 and a 12-month high of $9.73.

Institutional Trading of Rocket Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in RCKT. Maverick Capital Ltd. raised its stake in shares of Rocket Pharmaceuticals by 60.9% in the 2nd quarter. Maverick Capital Ltd. now owns 8,363,813 shares of the biotechnology company’s stock valued at $20,491,000 after purchasing an additional 3,164,595 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Rocket Pharmaceuticals by 12.6% in the 3rd quarter. Vanguard Group Inc. now owns 6,892,204 shares of the biotechnology company’s stock valued at $22,469,000 after acquiring an additional 769,743 shares during the last quarter. MPM Bioimpact LLC raised its position in shares of Rocket Pharmaceuticals by 141.2% during the 2nd quarter. MPM Bioimpact LLC now owns 3,903,081 shares of the biotechnology company’s stock valued at $9,563,000 after acquiring an additional 2,284,816 shares in the last quarter. Millennium Management LLC boosted its holdings in Rocket Pharmaceuticals by 52.0% in the third quarter. Millennium Management LLC now owns 3,570,391 shares of the biotechnology company’s stock worth $11,639,000 after purchasing an additional 1,221,554 shares during the period. Finally, Monaco Asset Management SAM increased its stake in Rocket Pharmaceuticals by 3.3% during the fourth quarter. Monaco Asset Management SAM now owns 2,987,296 shares of the biotechnology company’s stock valued at $10,485,000 after purchasing an additional 95,035 shares during the last quarter. Institutional investors own 98.39% of the company’s stock.

Insider Activity

In other news, General Counsel Martin Wilson sold 12,253 shares of Rocket Pharmaceuticals stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $3.31, for a total transaction of $40,557.43. Following the sale, the general counsel directly owned 683,376 shares of the company’s stock, valued at approximately $2,261,974.56. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Gaurav Shah sold 12,279 shares of the business’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $3.31, for a total value of $40,643.49. Following the completion of the transaction, the chief executive officer owned 1,052,045 shares in the company, valued at approximately $3,482,268.95. This trade represents a 1.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 29,415 shares of company stock valued at $97,398 over the last 90 days. Insiders own 24.76% of the company’s stock.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.